ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

REDX Redx Pharma Plc

15.00
0.00 (0.00%)
04 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Redx Pharma Plc LSE:REDX London Ordinary Share GB00BSNB6S51 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 15.00 12.00 17.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Panmure Gordon (UK) Limited Form 8.5 (EPT/RI) (2149T)

16/03/2023 9:48am

UK Regulatory


Redx Pharma (LSE:REDX)
Historical Stock Chart


From Dec 2022 to Dec 2024

Click Here for more Redx Pharma Charts.

TIDMREDX

RNS Number : 2149T

Panmure Gordon (UK) Limited

16 March 2023

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

   1.         KEY INFORMATION 
 
 (a) Name of exempt principal trader:                                                      Panmure Gordon (UK) Limited 
 (b) Name of offeror/offeree in relation to whose relevant securities this form relates:   REDX Pharma PLC 
  Use a separate form for each offeror/offeree 
                                                                                          ---------------------------- 
 (c) Name of the party to the offer with which exempt principal trader is connected:       REDX Pharma PLC 
                                                                                          ---------------------------- 
 (d) Date dealing undertaken:                                                              15 Mar 2023 
                                                                                          ---------------------------- 
 (e) In addition to the company in 1(b) above, is the exempt principal trader making       N/A 
 disclosures 
 in respect of any other party to this offer? 
 If it is a cash offer or possible cash offer, state "N/A" 
                                                                                          ---------------------------- 
 
   2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

   (a)        Purchases and sales 
 
    Class of relevant      Purchases/ sales       Total number of         Highest price per     Lowest price per unit 
        security                                     securities          unit paid/received         paid/received 
      10p Ordinary             Purchase                3,500                   0.4188                   0.4188 
                          ------------------  -----------------------  ----------------------  ----------------------- 
      10p Ordinary               Sales                 34,055                   0.455                   0.388 
                          ------------------  -----------------------  ----------------------  ----------------------- 
 
   (b)        Cash-settled derivative transactions 
 
    Class of relevant       Product description      Nature of dealing         Number of reference      Price per unit 
         security                 e.g. CFD         e.g. opening/closing a           securities 
                                                    long/short position, 
                                                   increasing/reducing a 
                                                    long/short position 
 
 
   (c)        Stock-settled derivative transactions (including options) 
   (i)         Writing, selling, purchasing, or varying 
 
   Class of       Product        Writing,      Number of       Exercise          Type       Expiry date   Option money 
   relevant     description    purchasing,     securities      price per         e.g.                        paid/ 
   security      e.g. call       selling,       to which         unit         American,                   received per 
                   option      varying etc.      option                        European                       unit 
                                                relates                          etc. 
 
 
   (ii)        Exercise 
 
   Class of relevant      Product description   Exercising/ exercised    Number of securities     Exercise price per 
        security            e.g. call option           against                                           unit 
 
 
   (d)        Other dealings (including subscribing for new securities) 
 
 Class of relevant security         Nature of dealing          Details   Price per unit (if applicable) 
                               e.g. subscription, conversion 
 
 
   3.         OTHER INFORMATION 
   (a)        Indemnity and other dealing arrangements 
 
 Details of any indemnity or option arrangement, or any agreement or understanding, formal 
  or informal, relating to relevant securities which may be an inducement to deal or refrain 
  from dealing entered into by the exempt principal trader making the disclosure and any party 
  to the offer or any person acting in concert with a party to the offer: 
  Irrevocable commitments and letters of intent should not be included. If there are no such 
  agreements, arrangements or understandings, state "none" 
 
 
   (b)        Agreements, arrangements or understandings relating to options or derivatives 
 
 Details of any agreement, arrangement or understanding, formal or informal, between the exempt 
  principal trader making the disclosure and any other person relating to: 
  (i) the voting rights of any relevant securities under any option; or 
  (ii) the voting rights or future acquisition or disposal of any relevant securities to which 
  any derivative is referenced: 
  If there are no such agreements, arrangements or understandings, state "none" 
 
 
 
 Date of disclosure:    16/03/2023 
 Contact name:          Mohammed Jamal 
                       --------------- 
 Telephone number:      020 7886 2780 
                       --------------- 
 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

FERDZGMFLVRGFZG

(END) Dow Jones Newswires

March 16, 2023 05:48 ET (09:48 GMT)

1 Year Redx Pharma Chart

1 Year Redx Pharma Chart

1 Month Redx Pharma Chart

1 Month Redx Pharma Chart

Your Recent History

Delayed Upgrade Clock